BBIO
NASDAQ
US
BridgeBio Pharma, Inc. - Common Stock
$73,15
▼ $-1,30
(-1,75%)
Vol. 1.2M
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$14.7B
ROE
-206,7%
Margine
-225,3%
D/E
827,29
Beta
1,13
52W
$27–$78
Consenso Wall Street
29 analisti · Apr 20269
Acquisto forte
19
Compra
1
Mantieni
0
Vendi
0
Vendita forte
96,6%
Rating Compra
Grafico dei Prezzi
Titoli simili
RVMD
Revolution Medicines Inc
$15.4B
MRNA
Moderna Inc
$11.5B
INCY
Incyte Corp
P/E 16,3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
NBIX
Neurocrine Biosciences Inc
P/E 33,0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
EXEL
Exelixis Inc
P/E 17,3
$11.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21,9
$11.4B
Utili
Tasso di battuta: 25,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,76 | $-1,00 | $-0,24 |
| Set 2025 | $-0,91 | $-0,95 | $-0,04 |
| Giu 2025 | $-0,86 | $-0,95 | $-0,09 |
| Mar 2025 | $-0,94 | $-0,88 | +$0,06 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $5.9M | $116.6M | $110.6M | $120.7M | $154.2M |
| Utile netto | — | -$265.1M | -$167.4M | -$181.9M | -$182.7M | -$192.9M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -206.7% | -206.7% | -206.7% | -206.7% | -206.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -164.5% | -329.2% | -329.2% | -329.2% | -225.3% | -225.3% |
| Gross Margin | 96.7% | 96.2% | 96.2% | 96.2% | 95.8% | 95.8% |
| D/E Ratio | — | 827.29 | 827.29 | 827.29 | 827.29 | 827.29 |
| Current Ratio | 5.19 | 5.19 | 5.19 | 5.19 | 3.88 | 3.88 |
Rapporti chiave
ROA (TTM)
-82,2%
P/S (TTM)
41,67
P/B
150,7
EPS (TTM)
$-4,19
CF/Share
$-3,94
Crescita ricavi 3A
+47,1%
52W High
$78,44
52W Low
$27,23
$27,23
Intervallo 52 settimane
$78,44
Salute finanziaria
Flusso di cassa libero
-$56.5M
Debito netto
$1.3B
Liquidità
$570.1M
Debito totale
$1.9B
Aggiornato al Dic 31, 2025
Як BBIO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка BBIO vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
41,7
▲
224%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
150,7
▲
6027%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість BBIO vs аналоги Biotechnology
ROE
-206,7%
▼
207%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-225,3%
▲
21%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
95,8%
▲
22%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-82,2%
▼
76%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя BBIO vs аналоги Biotechnology
D/E ratio
827,3
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
3,9
▼
13%
sotto
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
1,1
▲
16%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів BBIO
BBIO
Mediana peer
Industria
BBIO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
BBIO vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora